Antibody Caninization

BioVenic provides antibody caninization services, employing complementarity-determining region (CDR) grafting and other engineering techniques. Antibody caninization is modifying monoclonal antibodies derived from other species (commonly human or murine) to make them compatible with the canine immune system. Antibody caninized modification minimizes the likelihood of the dog's immune system recognizing the therapeutic antibody as foreign, which can lead to immune reactions and reduced efficacy. By aligning the antibody structure closely with natural canine antibodies, caninization enhances the safety and effectiveness of the therapeutic antibody treatment.

One-Stop Solution of Antibody Caninization

We specialize in providing comprehensive antibody caninization services to support the development of cutting-edge canine therapeutic antibodies. Our services encompass the entire caninization process, ensuring high-quality, customized solutions for veterinary pharmaceutical companies and research institutions.

Fig.1 CDR grafting in antibody engineering: from murine to feline antibody. (BioVenic Original)

Sequence Analysis and Selection

The process begins with an initial consultation, during which we work closely with you to understand your specific therapeutic goals and the target canine disease. We access the relevant antibody sequences from databases or samples you provide. We select the appropriate canine antibody framework, which will serve as the base for caninization, ensuring that the therapeutic antibody will be compatible with the canine immune system.

Genetic Engineering

In the genetic engineering phase, we focus on transferring the complementarity-determining regions (CDRs) from the original antibody to the selected canine framework regions(FR). CDR grafting is essential for preserving the antibody's specificity and binding properties.

Following this, we utilize advanced bioinformatics tools to optimize the antibody sequence. This optimization enhances the stability and binding affinity of the caninized antibody, ensuring it functions effectively within the canine biological environment.

Expression and Production

We proceed to recombinant expression of the antibodies, where the caninized antibodies are produced using mammalian cell systems. This approach ensures proper folding and functionality, which are crucial for the antibody's therapeutic efficacy. We employ advanced purification techniques to obtain high-purity antibodies, which are designed to produce antibodies that are not only effective but also safe for therapeutic use in canines.

In Vitro and In Vivo Testing

We offer comprehensive in vitro and in vivo testing to validate the efficacy and safety of the caninized antibodies. We conduct binding assays to confirm the specificity and affinity of the antibodies, ensuring they target the intended disease markers effectively. Our functional testing evaluates the therapeutic potential of the antibodies through various canine disease models. Additionally, we assess the immunogenicity of the antibodies in canine models to ensure that they do not provoke adverse immune reactions. This thorough testing process is crucial for developing safe and effective therapeutic antibodies for canine patients.

Fig.2 Comprehensive antibody engineering workflow: sequence to assay. (BioVenic Original)

Why Choose Us?

To overcome the immune response triggered by the mouse-derived therapeutic antibodies in dogs, BioVenic provides antibody caninization services to improve safety and maintain efficacy. Utilizing novel technologies, caninized therapeutic antibodies can exhibit more physiologically relevant performance in canines, and minimize the risk of immunogenicity. If you have the need for antibody caninization services, please contact us now!